Corvus Pharmaceuticals, Inc. (CRVS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CRVS Revenue Growth
CRVS Revenue Analysis (2014–2025)
As of May 9, 2026, Corvus Pharmaceuticals, Inc. (CRVS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, CRVS's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), TPVG, and ALEC (-79.2% YoY). Compare CRVS vs RCUS →
CRVS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRVSCurrent | $0 | - | - | - | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TPVG | $97M | - | - | 77.9% | |
 ALEC | $21M | -79.2% | -0.1% | -692.8% |
CRVS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-105,000 | - | $-42,971,000 | - |
| 2024 | $0 | - | $0 | - | $-27,548,000 | - |
| 2023 | $0 | - | $0 | - | $-23,407,000 | - |
| 2022 | $0 | - | $0 | - | $-32,565,000 | - |
| 2021 | $0 | - | $0 | - | $-38,630,000 | - |
| 2020 | $0 | - | $0 | - | $-43,760,000 | - |
| 2019 | $0 | - | $0 | - | $-48,854,000 | - |
| 2018 | $0 | - | $-847,000 | - | $-49,222,000 | - |
| 2017 | $0 | - | $-842,000 | - | $-56,524,000 | - |
| 2016 | $0 | - | $-594,000 | - | $-36,976,000 | - |
See CRVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRVS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRVS — Frequently Asked Questions
Quick answers to the most common questions about buying CRVS stock.
Is CRVS's revenue growth accelerating or slowing?
CRVS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CRVS's long-term revenue growth rate?
Corvus Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CRVS's revenue distributed by segment?
CRVS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.